← Back to all trials
Active Not Recruiting
NCT05729711
TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS)
Conditions: Bronchial Asthma (Only the Patients With Severe or Intractable Bronchial Asthma Which Could Not be Controlled With the Existing Therapy)
Sex: All
Healthy volunteers: No
Enrollment: 416
Sponsor: AstraZeneca
Location: Research Site Aichi
Summary
The purpose of the investigation is to confirm the followings under the post-marketing actual long-term use of Tezspire.
1. Development of related AEs
2. Contributing factors possibly having an impact on the safety and effectiveness
3. Development of unexpected related AEs
Eligibility Criteria
Inclusion Criteria:
* The evaluable patients are those treated with Tezspire for the first time due to "Bronchial asthma (only the patients with severe or intractable bronchial asthma which could not be controlled with the existing therapy)
Exclusion Criteria:
None
Source: ClinicalTrials.gov (NCT05729711). StuddyBuddy aggregates publicly available trial information.
